OBJECTIVE: Bladder cancer (BCa) is a disease of older persons, the incidence of which is expected to increase as the population ages. There is controversy, however, regarding the outcomes of radical cystectomy (RC), the gold standard treatment of high-risk BCa, in patients of advanced chronological age. The aim of our study was to assess the impact of patient age on pathological characteristics and recurrence-free and disease-specific survival following RC. METHODS: The records of 888 consecutive patients who underwent RC for transitional cell carcinoma (TCC) were reviewed. Age at RC was analyzed both as a continuous (yr) and categorical (< or =60 yr old, n=240; 60.1-70 yr old, n=331; 70.1-80 yr old, n=266; >80 yr old, n=51) variable. Logistic regression and survival analyses were performed. RESULTS: Higher age at RC, analyzed as a continuous or categorical variable, was associated with extravesical disease and pathological upstaging (all p<0.02). Older patients were less likely to receive postoperative chemotherapy (< or =60 yr: 32% vs. >80 yr: 14%, p=0.008). In both pre- and postoperative multivariate models, higher age at RC as a categorical variable was associated with BCa-specific survival (p<0.05). Patients >80 yr old had a significantly greater risk of disease recurrence than patients aged < or =60 yr (p<0.05). CONCLUSION: Greater patient age at the time of RC for BCa is independently associated with adverse outcomes. Better understanding of factors associated with postoperative outcomes in this growing segment of the population is necessary. Prospective corroboration and further refinement of similar analyses in other large datasets is needed.
OBJECTIVE:Bladder cancer (BCa) is a disease of older persons, the incidence of which is expected to increase as the population ages. There is controversy, however, regarding the outcomes of radical cystectomy (RC), the gold standard treatment of high-risk BCa, in patients of advanced chronological age. The aim of our study was to assess the impact of patient age on pathological characteristics and recurrence-free and disease-specific survival following RC. METHODS: The records of 888 consecutive patients who underwent RC for transitional cell carcinoma (TCC) were reviewed. Age at RC was analyzed both as a continuous (yr) and categorical (< or =60 yr old, n=240; 60.1-70 yr old, n=331; 70.1-80 yr old, n=266; >80 yr old, n=51) variable. Logistic regression and survival analyses were performed. RESULTS: Higher age at RC, analyzed as a continuous or categorical variable, was associated with extravesical disease and pathological upstaging (all p<0.02). Older patients were less likely to receive postoperative chemotherapy (< or =60 yr: 32% vs. >80 yr: 14%, p=0.008). In both pre- and postoperative multivariate models, higher age at RC as a categorical variable was associated with BCa-specific survival (p<0.05). Patients >80 yr old had a significantly greater risk of disease recurrence than patients aged < or =60 yr (p<0.05). CONCLUSION: Greater patient age at the time of RC for BCa is independently associated with adverse outcomes. Better understanding of factors associated with postoperative outcomes in this growing segment of the population is necessary. Prospective corroboration and further refinement of similar analyses in other large datasets is needed.
Authors: Lauren C Harshman; Gerold Bepler; Zhong Zheng; John P Higgins; Genevera I Allen; Sandy Srinivas Journal: BJU Int Date: 2010-12 Impact factor: 5.588
Authors: Thomas F Chromecki; Julian Mauermann; Eugene K Cha; Robert S Svatek; Harun Fajkovic; Pierre I Karakiewicz; Yair Lotan; Derya Tilki; Patrick J Bastian; Bjoern G Volkmer; Francesco Montorsi; Wassim Kassouf; Giacomo Novara; Hans-Martin Fritsche; Vincenzo Ficarra; Christian G Stief; Colin P Dinney; Eila Skinner; Karl Pummer; Yves Fradet; Shahrokh F Shariat Journal: World J Urol Date: 2011-10-19 Impact factor: 4.226
Authors: Thomas F Chromecki; Behfar Ehdaie; Giacomo Novara; Karl Pummer; Richard Zigeuner; Christian Seitz; Armin Pycha; Richard K Lee; Eugene K Cha; Pierre I Karakiewicz; Casey Ng; Jay D Raman; Felix K Chun; Hans-Martin Fritsche; Kazumasa Matsumoto; Wassim Kassouf; Thomas J Walton; Patrick J Bastian; Juan I Martínez-Salamanca; Douglas S Scherr; Shahrokh F Shariat Journal: World J Urol Date: 2011-04-17 Impact factor: 4.226
Authors: Ifeanyichukwu I Megwalu; Anna Vlahiotis; Mohamed Radwan; Jay F Piccirillo; Adam S Kibel Journal: Eur Urol Date: 2007-11-05 Impact factor: 20.096
Authors: Marco Bianchi; Quoc-Dien Trinh; Maxine Sun; Malek Meskawi; Jan Schmitges; Shahrokh F Shariat; Alberto Briganti; Zhe Tian; Claudio Jeldres; Shyam Sukumar; James O Peabody; Markus Graefen; Paul Perrotte; Mani Menon; Francesco Montorsi; Pierre I Karakiewicz Journal: Can Urol Assoc J Date: 2012-08 Impact factor: 1.862
Authors: Shahrokh F Shariat; Michael W Kattan; Andrew J Vickers; Pierre I Karakiewicz; Peter T Scardino Journal: Future Oncol Date: 2009-12 Impact factor: 3.404